📊 PMCB Key Takeaways
Is PharmaCyte Biotech, Inc. (PMCB) a Good Investment?
PharmaCyte is a pre-revenue biotech company burning $3.8M annually with no commercial operations or revenue generation, creating an unsustainable fundamental position despite adequate near-term liquidity. While the company maintains a strong balance sheet with $20.2M cash and minimal debt, the absence of revenue, substantial operating losses (-$15.0M), and negative cash flow indicate a high-risk development-stage entity with limited runway before capital depletion.
Why Buy PharmaCyte Biotech, Inc. Stock? PMCB Key Strengths
- Strong cash position of $20.2M with 12.33x current ratio ensures near-term operational continuity
- Minimal leverage with 0.01x debt-to-equity ratio significantly reduces financial distress risk
- Improved net loss trend (31.2% YoY improvement) indicates some operational progress despite remaining deeply unprofitable
PMCB Stock Risks: PharmaCyte Biotech, Inc. Investment Risks
- Zero revenue indicates pre-clinical/clinical stage development with no commercialized products generating cash inflow
- Negative operating cash flow of -$3.8M coupled with -$15.0M net loss reveals unsustainable burn rate threatening long-term viability
- Limited cash runway of approximately 5+ years at current burn rates assuming no acceleration in R&D spending or clinical trial costs
- Highly speculative biotech with binary clinical outcomes and execution risk inherent to therapeutic development
Key Metrics to Watch
- Operating cash flow burn rate and quarterly cash runway calculations
- Revenue emergence timeline and clinical trial advancement/approval status
- Changes in operating expenses and R&D spending trajectory
PharmaCyte Biotech, Inc. (PMCB) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 12.33x current ratio provides a solid financial cushion.
PMCB Profit Margin, ROE & Profitability Analysis
PMCB vs Healthcare Sector: How PharmaCyte Biotech, Inc. Compares
How PharmaCyte Biotech, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is PharmaCyte Biotech, Inc. Stock Overvalued? PMCB Valuation Analysis 2026
Based on fundamental analysis, PharmaCyte Biotech, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
PharmaCyte Biotech, Inc. Balance Sheet: PMCB Debt, Cash & Liquidity
PMCB Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: PharmaCyte Biotech, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.80 indicates the company is currently unprofitable.
PMCB Revenue Growth, EPS Growth & YoY Performance
PMCB Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | N/A | $746.9K | $-0.17 |
| Q2 2026 | N/A | -$1.5M | $-0.39 |
| Q1 2026 | N/A | -$8.4M | $-1.23 |
| Q3 2025 | N/A | -$619.5K | $-0.44 |
| Q2 2025 | N/A | -$393.4K | $-0.26 |
| Q1 2025 | N/A | -$3.2M | $-0.54 |
| Q3 2024 | N/A | -$619.5K | $-0.04 |
| Q2 2024 | N/A | -$393.4K | $-0.09 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
PharmaCyte Biotech, Inc. Dividends, Buybacks & Capital Allocation
PMCB SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for PharmaCyte Biotech, Inc. (CIK: 0001157075)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PMCB
What is the AI rating for PMCB?
PharmaCyte Biotech, Inc. (PMCB) has an AI rating of SELL with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PMCB's key strengths?
Claude: Strong cash position of $20.2M with 12.33x current ratio ensures near-term operational continuity. Minimal leverage with 0.01x debt-to-equity ratio significantly reduces financial distress risk.
What are the risks of investing in PMCB?
Claude: Zero revenue indicates pre-clinical/clinical stage development with no commercialized products generating cash inflow. Negative operating cash flow of -$3.8M coupled with -$15.0M net loss reveals unsustainable burn rate threatening long-term viability.
What is PMCB's revenue and growth?
PharmaCyte Biotech, Inc. reported revenue of $0.0.
Does PMCB pay dividends?
PharmaCyte Biotech, Inc. does not currently pay dividends.
Where can I find PMCB SEC filings?
Official SEC filings for PharmaCyte Biotech, Inc. (CIK: 0001157075) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PMCB's EPS?
PharmaCyte Biotech, Inc. has a diluted EPS of $-2.41.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is PMCB a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, PharmaCyte Biotech, Inc. has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is PMCB stock overvalued or undervalued?
Valuation metrics for PMCB: ROE of -39.4% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy PMCB stock in 2026?
Our dual AI analysis gives PharmaCyte Biotech, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PMCB's free cash flow?
PharmaCyte Biotech, Inc.'s operating cash flow is $-3.8M, with capital expenditures of N/A.
How does PMCB compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -39.4% (avg: 15%), current ratio 12.33 (avg: 2).